Despite blood cancers making up seven percent of all cancers worldwide, their disparate nature means they often go ‘unseen’. However, their economic impact is substantial; the total cost of blood cancers to the EU economy is €12 billion, and healthcare costs per patient are almost two times higher when compared to the average cost across all cancers.1
Awareness of blood cancers and their symptoms is low but their impact on people’s lives and the global economy is high. Through our ‘Make Blood Cancer Visible’ campaign, we are working with the global cancer community to change this and to build greater awareness of the true impact of these cancers.
Our partnerships and alliances take many forms, but our goal is always the same: to advance scientific research to deliver solutions that provide value to patients, physicians and society. However, advancement of scientific knowledge about disease drives demand for medical innovation. We rely on our European partners to help forge a policy environment that fosters the development of innovative technologies to address the challenges of disease for all patients.
#WeWontRest until we can deliver solutions that make blood cancers like multiple myeloma a chronic and manageable condition.
To find out more about the different types of blood cancer watch the video below, and share your support on social media for an inclusive policy environment that supports medical innovation for all blood cancer patients:
References
- Burns R, Leal J, Sullivan R, Luengo-Fernandez R. Economic burden of malignant blood disorders across Europe: a population-based cost analysis. Lancet Haematol. 2016 Aug;3(8):e362-70. Available at: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30062-X/fulltext. Last accessed October 2018